Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Roche
Biotech
AAIC: Roche ‘very interested’ in tau despite amyloid AD focus
Roche’s biggest bet in Alzheimer’s may be its phase 3-stage amyloid asset, but the pharma is keeping its options open when it comes to targeting tau.
James Waldron
Jul 15, 2026 8:42am
Roche ends 2 Huntington’s programs, including Ionis ASO
Jul 9, 2026 2:40pm
Genentech sees 103 layoffs, pens $490M breast cancer collab
Jul 6, 2026 7:30am
Roche orchestrates phase 3 lung cancer win over Amgen and BMS
Jul 2, 2026 8:30am
Roche launches Axelios 1, its gene sequencing rival to Illumina
Jun 29, 2026 9:03am
Exelixis’ Cabometyx successor misses primary endpoint in CRC trial
Jun 22, 2026 3:40pm
